Beijing Konruns Pharmaceutical Co., Ltd. Class A

Beijing Konruns Pharmaceutical Co., Ltd. Class A

SSSE:603590
23.73
CNY
-0.20
(-0.84%)
0.88EPS
36.56P/E
5.18BMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5
4.55
3.64
2.89
4.92
7.67
6.65
5.07
5.14
5.55
5.87
5.28
5.79
5.5
Basic EPS, GAAP
0.99
1.47
1.63
1.6
3.99
1.98
1.66
1.15
0.94
0.65
0.96
0.27
1.05
0.88
Free Cash Flow per Basic Share
0.88
0.81
1.22
-0.25
1.97
1.85
1.52
0.05
-0.6
0.15
0.63
0.44
0.39
- -
Dividend per Share
0.1
- -
- -
- -
- -
- -
0.5
0.5
0.35
0.3
0.22
0.34
0.65
0.41
Book Value per Share
2.6
4.07
5.69
7.29
11.29
15.52
17.05
19.24
18.05
18.29
19.12
19.73
20.2
19.8
Tangible Book Value per Share
1.6
3.09
4.79
6.47
10.55
15.01
16.67
13.51
11.84
11.85
12.24
12.98
13.02
12.46
Basic Weighted Avg Shares
120
120
120
120
120
133
160
159
157
156
157
156
158
157
Sales/Revenue/Turnover
598
544
436
346
591
1,022
1,066
809
810
867
920
825
915
863
Operating Margin (%)
18.75
30.13
37.75
46.93
32.48
25.81
22.64
18.38
16.4
15.83
15.9
15.52
21.7
18.11
Depreciation Expense
16
22
25
27
27
35
35
30
36
39
43
36
36
- -
Net Income, GAAP
118
176
195
192
479
264
266
183
148
101
150
42
166
138
Effective Tax Rate (%)
12.22
11.85
12.22
12.16
16.77
12.09
11.04
11.86
11.34
11.7
- -
44.6
10.68
15.81
Profit Margin (%)
19.79
32.3
44.77
55.36
81.08
25.82
24.96
22.67
18.27
11.71
16.35
5.11
18.14
15.98
Working Capital
-21
142
298
276
449
1,621
1,768
1,213
793
844
907
734
936
825
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
11
4
44
61
57
34
Total Equity
313
488
683
875
1,355
2,483
2,728
3,084
3,131
3,190
3,362
3,426
3,496
3,483
Return on Invested Capital (%)
- -
40.11
29.82
23.1
41.16
13.64
10.16
6.31
5.42
3.88
- -
0.61
4.89
- -
Return on Capital (%)
- -
43.82
33.34
24.6
42.1
12.14
10.21
6.3
4.15
2.51
- -
1.86
4.54
- -
Return on Common Equity (%)
- -
43.97
33.34
24.6
42.94
13.75
10.21
6.32
4.96
3.49
5.03
1.36
5.22
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
275
351
347
LT Borrowings
54
26
33
LT Finance Leases
1
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
159
159
161
Market Capitalization
5,874
4,613
5,179

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,323
1,390
1,347
Cash, Cash Equivalents & STI
787
821
800
Accounts Receivable, Net
272
303
276
Inventories
59
56
70
Total Current Liabilities
434
545
522
Payables & Accruals
- -
- -
- -
ST Debt
275
351
347
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.18%
2.55%
2.05%
Free Cash Flow
-220.36%
-222.08%
-8.79%
Net Income, GAAP
29.16%
43.74%
293.13%
Sales/Revenue/Turnover
11.71%
2.78%
10.87%
Total Cash Common Dividend
- -
14.57%
91.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
199
206
241
179
825
2025
212
249
- -
223
915
2026
215
248
177
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.27
0.24
0.21
-0.44
0.27
2025
0.28
0.29
- -
0.25
1.05
2026
0.3
0.31
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.31
0.01
0.34
2025
0.01
0.61
- -
0.01
0.65
2026
0.01
0.01
0.36
- -
- -

Company Description

CEO
Zhanqi Niu
Full Time Employees
793
Sector
Retail trade
Industry
Drugstore chains
Address
Building 3 Beijing BE China 102206
IPO Date
Aug 27, 2018
Website
konruns.cn
Business
Beijing Konruns Pharmaceutical Co.,Ltd. is a high-tech enterprise focused on the research, development, manufacturing, and commercialization of pharmaceutical products within China. The company is publicly traded on the Shanghai Stock Exchange, having been listed in August 2018. Its primary offerings include Viburnum hemagglutinin, marketed as Suling, a pioneering hemocoagulase preparation utilized to manage bleeding during and after surgical procedures. Beyond this, the firm provides products like Migexin salmon calcitonin nasal spray and Migasil salmon calcitonin injection. Konruns is actively advancing a robust pipeline of innovative and generic drug candidates, particularly in the fields of oncology and blood-related disorders, with several compounds such as CX1026, CX1003, KC1036, and KC1086 undergoing clinical trials for various advanced solid tumors and other conditions. The company, established in 2003, is headquartered in Beijing, China, and reported operating revenue of 692 million yuan for the first three quarters of 2025.